Serotin and Norephinephrine reuptake inhibitors - include Duloxetine and Desvenlafaxine Refer - Duloxetine

As desvenlafaxine is primarily metabilosed through conjugation drugs that affect the CYP 450 isoenzymes are unlikely to have a significant effect on desvenlafaxine levels. It should be used in caution with other serotonigic agents such as antidepressants, stimulants, 5HT , agonists and opioids, as the risk of developing serotonin syndrome may be increased

Major depressive disorder

Serotin and Norephinephrine reuptake inhibitors - include Duloxetine and Desvenlafaxine Refer - Duloxetine

Most common adverse effects reported were nausea and dizziness. Due to its noradrenergic action,desvenlafaxine may increase blood pressure and heart rate during therapy. Other minor adverse effects that may occur include diarrhea, anxiety, sexual dysfunctiion , abnormal bleeding and hyponatemia

Patients hypersensitive to Desvenlafaxine succinate, Venlafaxine Hydrocholride or any excepients in the formuation and patients taking monoamine Oxidase Inhibitors ( MAOIs)

Major depressive disorder

Desvenlafaxine 50mg to 100 mg extended -release tablet is recommended per day

Serotin and Norephinephrine reuptake inhibitors - include Duloxetine and Desvenlafaxine

Refer - Duloxetine

Pharmacodynamics

Desvenlafaxine acts by preventing thereuptaker of serotinin and norepinephrine by nerves after their release. Since uptake is an important mechansim for removing released neurotransmitters and terminating their actions on adjacent nerves, the reduced uptake caused by desvenlafaxine increases the effect of serotonin and norephinephrine in the brain.

Pharmacokinetics

Desvenlafaxine administered orally as single dose 50mg or 100mg (once-a - day) shows linear and dose proportional pharmacokinetics in a dose range between 100mg/day to 600mg/day. The mean terminal half-life is approximately 11 hours with maximum plasma concentration of 7.5hrs of oral administration. The bsolute bio-availability od desvenlafaxine oral formulation is found to be 80% and absorption minimally affected by food It undergoes minimal metabolism via the CYP 450 isoenzymes and 5% of ther dose is excreted unchanged in the urine.

Absorption minimally affected by food